Previous 10 | Next 10 |
2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...
2023-08-07 14:12:24 ET Shares of Gracell Biotechnologies (NASDAQ: GRCL) were up by more than 16% as of 2 p.m. on Monday after the clinical-stage biotech company announced a private stock placement of $150 million dollars. The company is scheduled to report second-quarter earning...
2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...
2023-08-07 08:12:35 ET Global clinical-stage biopharmaceutical company, Gracell Biotechnologies ( NASDAQ: GRCL ) jumped 14% on pre-market hours on Monday as it entered into an agreement for the private placement of 138.9M shares (equivalent to 27.78M ADS), at a purchase price eq...
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors PR Newswire Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of...
SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of canc...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is one of today's top gainers. The company's shares are currently up 24.61% on the day to $4. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the...
2023-06-30 12:31:22 ET Gainers: Cyteir Therapeutics ( CYT ) +39% . Renalytix ( RNLX ) +39% . Rackspace Technology ( RXT ) +29% . Friedman Industries ( FRD ) +23% . Gracell Biotechnologies ( GRCL ) +23% . CytomX Therapeutics (...
2023-06-20 17:42:47 ET Gainers: 2U ( TWOU ) +7% . Silk Road Medical ( SILK ) +4% . ROC Energy Acquisition ( ROC ) +4% . AXT ( AXTI ) +4% . CVB Financial ( CVBF ) +3% . Losers: LifeStance Health Group ( LFST ) ...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...